Date of Establishment Revenue Market Cap Corporate Address Management Details
Business Operation Background
1947 166.988 ( USD in Millions ) 12702.81876765 ( Rs. in Millions ) Sandoz House,Shivsagar Estate ,Dr Annie Besant Road Worli Mumbai-400018, Maharashtra www.novartis.in Chairperson - C Snook MD - R Shahani Directors - A Mirchandani, C Snook, Girish Tekchandani, H K Maniar, J Hiremath, P Jager, R Mehrotra, R Shahani Pharmaceuticals & Drugs Novartis India (NIL), incorporated in 1947, is a subsidiary of Swiss giant Novartis -- the world's second largest pharmaceutical company. The company finds its origin from three separate entities namely Geigy, Ciba, and Sandoz. Geigy was founded in 1758; Ciba was founded around 1860 and Sandoz was founded in 1886. In the year 1970 Ciba and Geigy merged and formed Ciba-Geigy. Much later in 1996 Sandoz Total Income - Rs. 9877.1 Million ( year ending Mar 2013) Net Profit - Rs. 1197.3 Million ( year ending Mar 2013) Girish Tekchandani Price Waterhouse
Financials Company Secretary Bankers Auditors
Novartis India (NIL), incorporated in 1947, is a subsidiary of Swiss giant Novartis -- the world's second largest pharmaceutical company. The company finds its origin from three separate entities namely Geigy, Ciba, and Sandoz. Geigy was founded in 1758; Ciba was founded around 1860 and Sandoz was founded in 1886. In the year 1970 Ciba and Geigy merged and formed Ciba-Geigy. Much later in 1996 Sandoz was merged with Ciba-Geigy. Together these three entities became one to form Novartis. Today, Novartis has 100,000 associates working across 140 countries. The company is engaged in manufacturing and marketing of drugs, pharmaceutical products and formulations for consumer healthcare and animal healthcare. Business division Pharmaceuticals- Under this the company currently owns 45 key marketed products in therapeutic area. Novartis owns products like Diovan HCT, Gleevec, Lamisil, Zometa are amongst others. Vaccines and Diagnostics- This division is a leader in providing products to fight more than 20 vaccinepreventable viral and bacterial diseases and blood-testing equipment. Currently the company owns vaccines for influenza meningitis, rabies, tick-borne encephalitis, haemophilus influenzae type b (hib), polio, diphtheria, tetanus and pertussis. Sandoz- This is the generic pharmaceutical division of company catering its products to areas like antibiotics, treatments for central-nervous-system disorders, gastrointestinal medicines, cardiovascular treatments and hormone therapies. Over-the-Counter- The Companys over-the-counter (OTC) products cater in area of analgesics, cough, cold,
allergy, gastrointestinal, skin care and smoking-cessation treatments, as well as mineral supplements. Animal Health- The company provides products for preventing and treatment of several widespread animal diseases and parasite infestations. The majority of these products are available by prescription through veterinarians. Novartis is also engaged in manufacturing of contact lenses and lens care products. Outlook The company and Medicines for Malaria Venture (MMV) launched a new pediatric formulation of Coartem for treatment of uncomplicated malaria in infants and children.
S.No 1 2 3 4 5
Name C Snook Girish Tekchandani R Shahani J Hiremath R Mehrotra
Designation Chairman Company Secretary Vice Chairman & Managing Director Non Executive Independent Director Non Executive Independent Director
Product Name Tablets (Pharmaceuticals) Injectables (Pharmaceuticals) Liquid - Orals (OTC) Tablets (Generics) Drug Formulations (Animal Health) Mission
Year 2013
Month 03
Sales Sales Quantity Value(Rs.Million) 0.00 3078.00
% of STO 33.95
2013
03
0.00
1605.80
17.71
2013 2013
03 03
0.00 0.00
940.80 559.10
10.38 6.17
2013
03
0.00
538.20
5.94
We want to discover, develop and successfully market innovative products to prevent and cure diseases, to ease suffering and to enhance the quality of life.
We also want to provide a shareholder return that reflects outstanding performance and to adequately reward those who invest ideas and work in our company. Vision We want to be recognized for having a positive impact on people's lives with our products,meeting needs and even surpassing external expectations. We strive to create sustainable earnings growth, ranking in the top quartile of the industry and securing long-term business success. We want to build a reputation for an exciting workplace in which people can realize their professional ambitions. We strive for a motivating environment where creativity and effectiveness are encouraged andwhere cutting-edge technologies are applied. In addition, we want to contribute to society through our economic contribution, through the positive environmental and social benefits of our products, and through open dialogue with our stakeholders History Novartis was created in 1996 through the merger of Ciba-Geigy and Sandoz, two companies with a rich and diverse corporate history. Throughout the years, Novartis and its predecessor companies have discovered and developed many innovative products for patients and consumers worldwide. To learn more about our history and key achievements, click on the timeline above. Achievements 08 August, 2012 Winners of BioCamp 2012 (l-r) Dr Girish Naik, Esha Kakkar and Sagar Laygude 30 January, 2012 Novartis extends commitment to help achieve final elimination of leprosy 31 December, 2011 Novartis India Announces Results for the Financial Results for the Quarter and Nine Months ended 31st December 2011 30 September, 2011 Novartis India Announces Results for the Quarter and Half-Year ended 30 September 2011
Conclusion Novartis a company who come up with different mergers and acquisitions is now standing at a point having sales in billions of dollars with the market leadership in patented products andgeneric medication. Novartis is growing well as compared to its major rivals if we compare itwith Johnson & Johnson.The state of the art research and development labs in different parts of the world coveringdifferent aspects of bio technology helped for the cure of the human body. The research ondifferent aspects on viral, bacterial diseases along with the diagnostics of diseases takes place inthe research labs of Novartis.The leadership in the patented drugs helped Novartis to generate the fruitful sales as compared toits rivals and not only in Patented but also in generic drugs Novartis is doing brilliantly. Thediverse work force form different parts of the world work in Novartis for research anddevelopment and with the blend of mix cultures Novartis is catering the overall market needs.
